Syngene International Ltd. is a leading Integrated Innovation Partner and CRDMO, for the global pharmaceutical, biopharma, biotechnology, and life sciences investment sectors. By combining discovery science, development expertise, and scalable manufacturing under one roof, we eliminate handoff delays, anticipate technical challenges, and align strategies to shorten timelines and reduce risk.

As an innovation partner, we connect every stage from concept to IND. With expertise across biologics, ADCs, and targeted protein degradation, we deliver speed, scientific depth, and strategic alignment. Our proprietary SynTACs™ platform advances induced proximity-based therapeutics such as PROTACs, while our AI-driven ecosystem—Syn.AI™, SARchitect™, and SynTIPS™—optimizes design, accelerates analysis, and delivers actionable insights. Powered by our SynVent™ integrated discovery engine, we transform early-stage ideas into viable clinical candidates.

Through versatile partnering structures and tailored business models, Syngene supports more than 400 global customers—including leading biotech innovators and multinational companies such as BMS, GSK, Zoetis, and Merck KGaA—to accelerate drug pipelines with capital efficiency, scientific rigor, and world-class manufacturing excellence.